Staccato Loxapine Pulmonary Safety in Patients With Asthma

Pulmonary Safety of Staccato® Loxapine for Inhalation in Subjects With Asthma

The purpose of this study is to assess the safety of 2 inhaled doses of Staccato Loxapine within a day in patients with asthma.

Inclusion Criteria:

• History of mild to moderate persistent asthma for at least 6 months with pre-bronchodilator FEV1 ≥60% of predicted value.

Exclusion Criteria:

• History of COPD, or any other acute or chronic pulmonary disease